Zealand Pharma
ZEAL.COZEAL.CO · Stock Price
Historical price data
Overview
Zealand Pharma's mission is to develop transformative peptide-based medicines that address the root causes of metabolic and gastrointestinal diseases, aiming to increase healthspan rather than merely treat symptoms. The company has achieved significant validation through strategic partnerships with major pharmaceutical players and has built a robust clinical pipeline anchored by its dual and triple agonists for obesity. Its strategy combines internal R&D excellence with selective collaborations to accelerate development and maximize global commercial reach.
Technology Platform
A proprietary peptide engineering platform enabling the design of long-acting, selective, and multi-target peptide agonists, with core expertise in GLP-1 receptor biology and multi-receptor agonist design for metabolic diseases.
Pipeline
44| Drug | Indication | Stage | Watch |
|---|---|---|---|
| glepaglutide | Short Bowel Syndrome | Phase 3 | |
| Glepaglutide | Short Bowel Syndrome | Phase 3 | |
| dasiglucagon + placebo + GlucaGen HypoKit | Hypoglycemia | Phase 3 | |
| glepaglutide + Placebo | Short Bowel Syndrome | Phase 3 | |
| Glepaglutide | Short Bowel Syndrome | Phase 3 |
Funding History
1FDA Approved Drugs
2Opportunities
Risk Factors
Competitive Landscape
Zealand competes directly with giants like Novo Nordisk and Eli Lilly in the incretin space. Its advantages include deep peptide specialization, strategic partnerships for development/commercialization, and a pipeline of mechanistically differentiated multi-agonists. The primary challenge is the rapid pace of competitor innovation.